Table 2.
Comparison of clinical and laboratory parameters during the study period
| Baseline | 12 weeks | 24 weeks | P value | |||
|---|---|---|---|---|---|---|
| N = 40 | N = 40 | N = 40 | Baseline vs 12 weeks | Baseline vs 24 weeks | 12 weeks vs 24 weeks | |
| Joint counts | ||||||
| Swollen (0–66) | 3.0 (0.8–5.3) | 0.0 (0.0–2.0) | 0.0 (0.0–1.0) | < 0.001* | < 0.001* | 1.000 |
| Tender (0–68) | 4.5 (3.0–7.3) | 2.0 (0.0–2.0) | 1.0 (0.0–2.0) | < 0.001* | < 0.001* | 1.000 |
| LEI | 0.0 (0.0–1.3) | 0.0 (0.0–0.0) | 0.0 (0.0–0.0) | 0.064 | 0.011* | 1.000 |
| Patients with dactylitis | 6 (15) | 1 (2.5) | 2 (5) | 0.011* | 0.062 | 1.000 |
| DAPSA | 22.9 (17.9–28.7) | 10.7 (6.9–13.6) | 6.0 (3.1–12.8) | < 0.001* | < 0.001* | 1.000 |
| PASI | 13.0 (4.4–16.0) | 1.0 (0.0–6.5) | 0.0 (0.0–2.0) | < 0.001* | < 0.001* | 0.143 |
| PASI 100 | NA | 11/33a (33.3) | 17/33 (51.5) | NA | NA | 0.007* |
| PASI 90 | NA | 13/33a (39.4) | 22 (66.6) | NA | NA | 0.225 |
| PASI 75 | NA | 14/33a (42.4) | 23/33a (69.7) | NA | NA | 0.278 |
| Pain VAS | 7.0 (6.0–8.0) | 3.0 (2.0–4.3) | 2.0 (1.0–5.0) | < 0.001* | < 0.001* | 1.000 |
| PGA | 7.5 (6.5–8.0) | 3.0 (2.0–4.0) | 2.0 (1.0–4.5) | < 0.001* | < 0.001* | 1.000 |
| CRP (mg/L) | 2.9 (0.2–3.8) | 1.6 (0.2–2.1) | 1.2 (1.3) [0.5] | 0.060 | 0.001* | 0.613 |
Data are presented as median (IQR) or n (%)
IQR interquartile range, LEI Leeds Enthesitis Index, DAPSA Disease Activity in Psoriatic Arthritis, PASI Psoriasis Area and Severity Index, VAS visual analog scale, PGA Patient Global Assessment, CRP C-reactive protein, NA not applicable
aSeven patients were excluded from this analysis because of a baseline PASI < 3
*Statistically significant